Skip to content

Our Story

A leading regenerative medicine company committed to driving change and improving patient outcomes

Since day one, we have remained steadfast in our mission to improve the lives of patients worldwide.

Our commitment to disruptive, meaningful innovation goes beyond mere advancement. It’s a dedication to setting new standards that challenge the status quo and push the limits of what’s possible. We believe innovation should be purposeful in how it improves the standards of care and ultimately, patient outcomes. If there is a better way, we will dream it up, and relentlessly strive to make it a reality.

“When Humacyte was first founded, many people thought our goal of creating an off-the-shelf human-derived vessel was the stuff of dreams. The twenty years of dedication that led to this point brought forth a new reality. We don’t take for granted the trust from our patients and caregivers in our platform. Every vessel and every person are an indelible part of our historic journey.

Laura Niklason, M.D., Ph.D.
Co-Founder and CEO
Our Vision
To be the world leader in regenerative medicine, revolutionizing the best science and technology to improve and save the lives of those suffering from injury and disease.

Key facts:

Developed a
first-in-class
bioengineering
technology
and manufacturing
platform

Granted Regenerative Medicine Advanced Therapy (RMAT)
designation by the U.S. FDA for the Acellular Tissue Engineered Vessel (ATEV™) in Vascular Trauma, AV Access, and PAD

Platform science has potential to be leveraged
across many clinical applications and indications

Highly scalable
cell sourcing and manufacturing are in place

Outreach

Humanitarian aid for vascular trauma injuries in Ukraine.

Our year-long humanitarian program in Ukraine, provided the investigational ATEV to five hospitals on the frontlines of the conflict, beginning in June 2022. At the request of Ukrainian surgeons, we worked closely with the International Office of the FDA and the Ukrainian Ministry of Health to obtain approval for the program. Training was conducted through video conference. In the end, nineteen patients were treated with investigational ATEVs for vascular injuries during the program.

Results published in Journal of Vascular Surgery – Vascular Science

You are now leaving humacyte.com.

You are now leaving humacyte.com. This link leads to symvess.com, which is intended for United States residents only. By clicking this link you verify that you are a United States resident.